Balancing needs and means: The dilemma of the β-cell in the modern world

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 4, 2009, Pages 1-9

  Leibowitz, G ^a   Kaiser, N ^a   Cerasi, E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Animal models of diabetes; Gluco lipotoxicity; Insulin secretion; MTOR; Prediabetes; Type 2 diabetes pathophysiology; cell death; cell function

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTINUOUS INFUSION; DIABETOGENESIS; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PSAMMOMYS OBESUS; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM; GENETIC VARIATION; GERBILLINAE; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PROTEINS; SIROLIMUS;

EID: 70350309323     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01101.x     Document Type: Article

References (62)

1. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab 2008, 8:186-200.
2. Kotchen TA, Fauci AS, Braunwald E, Kasper DL. Hypertensive vascular disease. Harrison's Online 2008, http://www.accessmedicine.com/resourceTOC.aspx?resourceID=4, In:, eds., New York, McGraw-Hill
3. Reaven G. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev 1993, 9(Suppl. 1):5S-12S.
4. Saltiel AR. The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular disease. J Clin Invest 2000, 106:163-164.
5. Cerasi E, Lefebvre P, Pipeleers D. Insulin secretion in diabetes. The Pathology of the Endocrine Pancreas in Diabetes 1988, 191-218. In:, eds., Heidelberg, Springer Verlag
6. Gerich JE. Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 2000, 85:2113-2115.
7. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of type 2 diabetes: is a divorce possible?. Diabetologia 1995, 38:992-997.
8. Cavaghan MK, Ehrman DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
9. Cerasi E, Boitard C, Efendic S, Ferrannini E, Henquin JC, Steiner DF. The islet in type 2 diabetes: Back to central stage. Diabetes 2001, 50(Suppl. 1):S1-S3.
10. Della Casa L, del Rio G, Glaser B, Cerasi E. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. Am J Med 1991, 90:37S-45S.
11. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
12. Weng J, Li Y, Xu W. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
13. Jacinto E. What controls TOR?. IUBMB Life 2008, 60:483-496.
14. Leibowitz G, Cerasi E, Ketzinel-Gilad M. The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):157-169.
15. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004, 167:399-403.
16. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
17. Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 2004, 279:35298-35305.
18. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006, 26:63-76.
19. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006, 3:393-402.
20. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005, 146:1473-1481.
21. Um SH, Frigerio F, Watanabe M. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
22. Kaiser N, Nesher R, Donath MY. Psammomys obesus, a model for environment-gene interactions in type 2 diabetes. Diabetes 2005, 54(Suppl. 2):S137-S144.
23. Kaiser N, Yuli M, Uckaya G. Dynamic changes in β-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus: impact of glycemic control. Diabetes 2005, 54:138-145.
24. Fraenkel M, Ketzinel-Gilad M, Ariav Y. mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57:945-957.
25. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004, 14:1650-1656.
26. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005, 280:2282-2293.
27. Shapiro AM, Ricordi C, Hering BJ. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355:1318-1330.
28. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006, 49:2341-2349.
29. Zhang N, Su D, Qu S. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006, 55:2429-2436.
30. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005, 90:493-500.
31. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006, 55:S2-S5.
32. Cerasi E, Luft R. Plasma-insulin response to sustained hyperglycaemia induced by glucose infusion in human subjects. Lancet 1963, 282:1359-1361.
33. Lerner RL, Porte D. Acute and steady-state insulin responses to glucose in nonobese diabetic subjects. J Clin Invest 1972, 51:1624-1631.
34. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
35. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):32-42.
36. Kaiser N, Leibowitz G. Failure of beta-cell adaptation in type 2 diabetes: lessons from animal models. Front Biosci 2009, 14:1099-1115.
37. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
38. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 2008, 29:351-366.
39. Laybutt DR, Preston AM, Akerfeldt MC. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007, 50:752-563.
40. Lai E, Bikopoulos G, Wheeler MB, Rozakis-Adcock M, Volchuk A. Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2008, 294:E540-E550.
41. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 2006, 147:3398-3407.
42. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29:42-61.
43. Fonseca SG, Lipson KL, Urano F. Endoplasmic reticulum stress signaling in pancreatic beta-cells. Antioxid Redox Signal 2007, 9:2335-2344.
44. Ortsäter H, Sjöholm A. A busy cell-endoplasmic reticulum stress in the pancreatic beta-cell. Mol Cell Endocrinol 2007, 277:1-5.
45. Poitout V, Robertson RP. Minireview: Secondary β-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
46. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002, 51(Suppl. 3):S405-S413.
47. Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic β-cells via activation of mTORC1. PLoS ONE 2009, 4:e4954.
48. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997, 100:1166-1173. European Group for the Study of Insulin Resistance (EGIR)
49. Edstrom K, Cerasi E, Luft R. Insulin response to glucose infusion during pregnancy. A prospective study of high and low insulin responders with normal carbohydrate tolerance. Acta Endocrinol (Copenh) 1974, 75:87-104.
50. Devlieger R, Casteels K, Van Assche FA. Reduced adaptation of the pancreatic B cells during pregnancy is the major causal factor for gestational diabetes: current knowledge and metabolic effects on the offspring. Acta Obstet Gynecol Scand 2008, 87:1266-1270.
51. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002, 32(Suppl. 3):35-45.
52. Cerasi E, Cobelli C, Bergman RN. Differential actions of glucose on insulin release: reevaluation of a mathematical model. Carbohydrate Metabolism 1981, 3-22. In:, eds., Chichester, John Wiley & Sons
53. Cerasi E, Luft R. Further studies on healthy subjects with low and high insulin response to glucose infusion. Acta Endocrinol (Copenh) 1967, 55:305-329.
54. Efendic S, Cerasi E, Elander I. Studies on low insulin responders. Glucose tolerance and insulin response to intravenous and oral glucose challenges in 226 normal subjects and 25 subjects with mild or chemical diabetes. Acta Endocrinol (Copenh) 1979, 90(Suppl. 224):5-32.
55. Alvarsson M, Wajngot A, Cerasi E, Efendic S. K-value and low insulin secretion in a non-obese white population predicted glucose tolerance after 25 years. Diabetologia 2005, 48:2262-2268.
56. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001, 44:929-945.
57. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response?. Acta Endocrinol (Copenh) 1967, 55:330-345.
58. Iselius L, Lindsten J, Morton NE. Genetic regulation of the kinetics of glucose-induced insulin release in man. Studies in families with diabetic and non-diabetic probands. Clin Genet 1985, 28:8-15.
59. Florez JC. The genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 2008, 93:4633-4642.
60. Pascoe L, Frayling TM, Weedon MN. Beta cell glucose sensitivity is decreased by 39% in non-diabetic individuals carrying multiple diabetes-risk alleles compared with those with no risk alleles. Diabetologia 2008, 51:1989-1992.
61. Cerasi E, Luft R. " What is inherited-what is added" hypothesis for the pathogenesis of diabetes mellitus. Diabetes 1967, 16:615-627.
62. Neel JV. The " thrifty genotype" in 1998. Nutr Rev 1999, 57:S2-S9.